Cargando…

Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement

Detalles Bibliográficos
Autores principales:	Fleming, Andrew B., Raabe, Vanessa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187833/ https://www.ncbi.nlm.nih.gov/pubmed/32361326 http://dx.doi.org/10.1016/j.jcv.2020.104388

Ejemplares similares

Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!
por: Sanfilippo, F., et al.
Publicado: (2020)

Current Perspectives of convalescent plasma therapy in COVID-19
por: Sahu, Kamal Kant, et al.
Publicado: (2020)

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
por: Joyner, Michael J., et al.
Publicado: (2021)

Functional Antibodies in COVID-19 Convalescent Plasma
por: Herman, Jonathan D., et al.
Publicado: (2021)

Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
por: Raadsen, Matthijs P., et al.
Publicado: (2021)

The resurgence of convalescent plasma therapy
por: The Lancet Haematology
Publicado: (2020)

Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency
por: Lang-Meli, Julia, et al.
Publicado: (2021)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021)

Challenges of Convalescent Plasma Therapy on COVID-19
por: Zhao, Qian, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic
por: Samad, Nandeeta, et al.
Publicado: (2020)

COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks
por: Noor, Rashed, et al.
Publicado: (2021)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration
por: Cain, Wesley V, et al.
Publicado: (2022)

Editorial: Updates on convalescent plasma and monoclonal antibody therapies for infectious disease in patients with primary immunodeficiency
por: Condino-Neto, Antonio, et al.
Publicado: (2022)

Convalescent plasma: Alternative or promising therapy?
por: Mina, Fahmida Begum, et al.
Publicado: (2021)

POTS May Be Underestimated in Post-COVID Assessments
por: Miglis, Mitchell G., et al.
Publicado: (2022)

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
por: Morgenlander, William, et al.
Publicado: (2020)

COVID‐19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?
por: Askenase, Philip W.
Publicado: (2020)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

Convalescent Plasma Therapy for COVID-19: State of the Art
por: Focosi, Daniele, et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

Convalescent plasma as a potential therapy for COVID-19
por: Chen, Long, et al.
Publicado: (2020)

The Three Pillars of COVID-19 Convalescent Plasma Therapy
por: Franchini, Massimo, et al.
Publicado: (2021)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Natarajan, Harini, et al.
Publicado: (2021)

Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions
por: Bonetti, Tatiana Carvalho de Souza, et al.
Publicado: (2021)

Convalescent plasma may be a possible treatment for COVID-19: A systematic review
por: Wang, Ying, et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Convalescent Plasma Therapy for Coronavirus Disease 2019
por: Choi, Jun Yong
Publicado: (2020)

The true historical origin of convalescent plasma therapy
por: Marson, Piero, et al.
Publicado: (2020)

Convalescent plasma for administration of passive antibodies against viral agents
por: Di Minno, Giovanni, et al.
Publicado: (2020)

Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
por: Clark, Natasha M, et al.
Publicado: (2021)

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
por: Herman, Jonathan D., et al.
Publicado: (2022)

Reply: POTS May Be Underestimated in Post-COVID Assessments
por: Jamal, Sameer M., et al.
Publicado: (2022)

Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates
por: Verma, Henu Kumar, et al.
Publicado: (2020)

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
por: Devos, Timothy, et al.
Publicado: (2022)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

Risk–benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19
por: Dhanasekaran, Sivaraman, et al.
Publicado: (2020)

Effectiveness of convalescent plasma therapy in severe COVID-19 patients
por: Duan, Kai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ijblh15lhulrjnkc6igcgrjdno